A DEFECT IN THE METABOLISM OF TYROSINE AND PHENYLALANINE IN PREMATURE INFANTS. III. DEMONSTRATION OF THE IRREVERSIBLE CONVERSION OF PHENYLALANINE TO TYROSINE IN THE HUMAN ORGANISM

By S. Z. LEVINE, MARGARET DANN, AND ELEANOR MARPLES

(*From the New York Hospital and the Department of Pediatrics, Cornell University Medical College, New York City*)

In preceding papers (1, 2), it was shown that premature infants fed vitamin C-free cow's milk mixtures, high in protein (5 grams or more per kgm. per day), exhibit a spontaneous defect in their metabolism of tyrosine and phenylalanine, manifested by the urinary excretion of 1-p-hydroxyphenyllactic and p-hydroxyphenylpyruvic acids. The defect was accentuated by feeding these subjects either amino acid in pure form. Full-term infants fed similar diets did not show the defect spontaneously but it could be induced in them by the ingestion of a single dose (1.0 gram per kgm.) of either amino acid. It was further shown that the administration of 1-ascorbic acid in adequate dosage abolished the spontaneous and artificially induced defect in both premature and full-term infants.

The presence of this metabolic aberration prompted a more detailed study of the response of infants to repeated oral doses of tyrosine and phenylalanine, with and without dietary vitamin C. In this study, the assays for urinary aromatic organic acids were supplemented by urinary assays for the amino acids themselves. These modified procedures threw further light on the pathways of intermediary aromatic amino acid metabolism and provided evidence of the irreversible conversion of phenylalanine to tyrosine by the living, normal human organism.

REVIEW OF THE LITERATURE

Available evidence establishes that the animal organism is able to form tyrosine and its derivatives from phenylalanine. The evidence is derived from three main lines of experimental approach: perfusion experiments, animal studies, and human observations.

Perfusion experiments

Following perfusion of dogs' livers with dog's blood containing d,1-phenylalanine, Embden and his coworkers (3) were able to isolate 1-tyrosine from the blood. They concluded that the conversion occurred by oxidation of the benzene ring, either directly or through the intermediation of p-hydroxyphenylpyruvic acid by simultaneous oxidative deamination of the side chain, the keto acid having previously been shown to form 1-tyrosine in liver perfusion experiments (4).

Animal studies

These studies demonstrate: *A.* the essential nature of phenylalanine as a dietary component for the growing rat and the non-essential nature of tyrosine, the evidence indicating that the tyrosine of body protein on tyrosine-free diets is synthesized *in vivo* from dietary phenylalanine (5); *B.* the presence of tyrosine derivatives (p-hydroxyphenylpyruvic acid, p-hydroxyphenyllactic acid, homogentisic acid, and even tyrosine itself) in the urine of white rats (6), scorbutic guinea pigs (7), and rabbits (8), following ingestion of phenylalanine; and *C.* the deposition of deutero-tyrosine in the body of rats from ingested d,1-deutero-phenylalanine (9) and deutero-phenyllactic acid (10).

Human observations

All previously reported human observations except those on infants (1, 2) were made on patients suffering from inborn errors of aromatic amino acid metabolism. Neubauer and Falta (11) and later workers (12) found that alkaptonuric patients who spontaneously excrete homogentisic acid augment their urinary excretion of

this acid when fed phenylalanine or its derivatives, phenylpyruvic and phenyllactic acids. Medes (13), in a single case of tyrosinosis, characterized by the spontaneous excretion of p-hydroxyphenyl-pyruvic acid, found that the ingestion of phenyl-alanine led to a marked increase in the urinary output of this keto derivative of tyrosine, and to the appearance in the urine of the hydroxy de-rivative of tyrosine, p-hydroxyphenyllactic acid, and, in lesser amounts, of tyrosine itself. In con-trast to the above observations, it is interesting to note that in the metabolic aberration, phenyl-pyruvic oligophrenia, characterized by the spon-taneous excretion of phenylpyruvic acid, the ad-ministration of phenylalanine is entirely without effect on the urinary output of tyrosine or its keto and hydroxy derivatives (14).

Except for the single case recorded by Medes (13), none of the published studies present direct evidence of an *in vivo* conversion of phenylalanine to tyrosine in the human organism and the ques-tion may properly be asked whether the demon-strated conversion in this single instance repre-sents the customary normal pathway of human intermediary metabolism. The metabolic defect, previously described in infants, provided a means of studying this conversion and its irreversibility in the normal human organism.

METHODS

Subjects

Eight healthy male premature infants, ranging in age from 8 to 22 days and weighing from 1.87 to 2.34 kgm. at the start of observations, were studied on diets of vitamin C-free cow's milk throughout periods of from 7 to 44 days, for a total of 129 days. Two male full-term infants, aged 17 and 20 days and weighing 3.88 and 3.54 kgm. at the start of observations, were studied on similar diets in periods of 13 and 12 days, respectively. All infants resided in a constant temperature and humid-ity room and were under the supervision of 4 specially trained nurses whose duties consisted of the preparation of diets, the collection of urine, and the general care of the infants. Only one or occasionally 2 infants were studied at one time.

All of the infants took their feedings well and gained weight. During test periods of amino acid administra-tion, transient abdominal distention was frequently ob-served, but regurgitation or vomiting was not frequent except in the case of A. V., who vomited small parts of many feedings. Increased frequency of defecation, and curds in the stools, were observed in 2 infants (R. Fo. and G. H.) during test periods.

Diets

A detailed description of the basal diets was given in the previous paper (2.b). Briefly, they consisted of dilutions of powdered cow's milk with cane sugar and provided approximately 150 cc. of fluid, 120 to 130 calories, and 5 to 7 grams of protein per kgm. per 24 hours. Chemical analysis, using a modification of Bessey's method (15) revealed the absence of vitamin C in the milk used.[1] Twenty drops of a vitamin A and D concentrate (perco-morph oil) were also given daily.

Supplements

Following adequate fore-periods of constant diet, all of the infants were given either 1-tyrosine or d, 1-phenyl-alanine, in amounts ranging from 0.25 to 2.00 grams per kgm. per 24 hours, for from 1 to 5 successive days. The amino acid was mixed with small amounts of sterile water and incorporated in repeated small portions of formula at one or 2 feedings, until it was quantitatively ingested.

Of the 10 infants, 3 received no ascorbic acid during the study. One infant (R. K.) was given this vitamin for some time prior to as well as during amino acid in-gestion. In the 6 remaining subjects, a series of ob-servations was made with amino acid administration while on a vitamin C-free diet, and repeated with con-current ingestion of varying dosage of 1-ascorbic acid.

Urine

The method for collecting urine separately from feces in infants was described in previous papers (16.a, b). Quantitative collections of urine were made throughout all observations and analyzed at the end of each 24- or occasionally 12-hour period. The 3 compounds giving the Millon reaction, p-hydroxyphenylpyruvic acid, p-hydroxyphenyllactic acid, and tyrosine, were determined in the untreated urine by the Folin-Ciocalteu method (17). The urine was also analyzed separately for p-hydroxy-phenylpyruvic acid by reduction of phosphomolybdic acid in acid solution, as described by Medes (13). Tyrosine, the only one of these 3 compounds insoluble in ether, was determined in the ether-extracted urine (17) after sepa-ration by continuous extraction for 24 hours. The dif-ference between the total Millon-reacting group ex-pressed as tyrosine, and the sum of the keto acid and tyrosine afforded a quantitative estimate of p-hydroxy-phenyllactic acid (2.a). In urine containing large amounts of ascorbic acid, this compound, by its reducing action on phosphomolybdic acid, yielded falsely high values for p-hydroxyphenylpyruvic acid and correspond-ingly falsely low values for p-hydroxyphenyllactic acid. For this reason, only the *in toto* values for the 2 ether-soluble derivatives of tyrosine are given in Table II and Figure 1 for all urinary specimens in which ascorbic acid was present in interfering amounts. Phenylalanine

was determined in the ether-extracted urine by the Kapeller-Adler method (18), interfering substances (aromatic organic acids) having been removed by preliminary extraction with ether. Only in observations on 2 infants (W. B. and R. S.) was tyrosine removed by oxidation with potassium permanganate in the cold (18) prior to the determination of phenylalanine. In the ether-extracted urines of one of these infants (W. B.), phenylalanine was determined both before and after this procedure. It was found that each milligram of tyrosine actually present accounted for approximately 0.2 mgm. of apparent phenylalanine. Phenylpyruvic acid was estimated by measuring the color produced with ferric chloride, as outlined by Jervis and his coworkers (19).

Feces

Estimates of the fecal loss of amino acids (phenylalanine (19) and tyrosine (17)) following ingestion were made in two series of observations (R. S. following tyrosine ingestion and L. G. after phenylalanine).

RESULTS

The detailed experimental data are presented in Tables I and II, the latter showing specifically

the effect of ingestion of the aromatic amino acids, phenylalanine and tyrosine, on the urinary excretion of the former and its keto derivative, and of the latter and its keto and hydroxy derivatives.

Controls

For each subject, a control period of constant diet and urine collection preceded amino acid ingestion. Except for G. H., whose formula was changed only 2 days before the onset of observations, all of the infants had been receiving the control diet of relatively high protein content (5 to 7 grams per kgm. of body weight) for at least 5 days. The control figures for urinary metabolites, given in Table II, represent the last 12 or 24 hours of constant diet before amino acid administration. In 7 of the 10 infants, including G. H., urinary analyses were also made for preceding days of the fore-periods, and the figures (not shown in the table) checked closely with the ones given in the table.

TABLE I

Age of subjects; nutritional status; experimental periods

Subjects Birth wt.	Experimental period	Supplement fed			Number of days	Age		Weight		Nitrogen average†	
		Amino acid		Ascorbic acid		Start	End	Start	End	Intake‡	Urine
		Type*	Average								
kgm.			*grams per day*			*days*		*kgm.*		*mgm. per kgm. per day*	
PREMATURES											
J. C.											
1.98	Fore				4	12	15	2.16	2.28	935	550
	Test	T	2.30		4	16	19	2.28	2.34	995	586
	Test	T	4.74		1	20		2.37		1047	568
	After				3	21	23	2.41	2.49	928	528
G. H.											
2.06	Fore				2	8	9	2.03	2.12	1007	308
	Test	T	2.20		4	10	13	2.12	2.24	1042	466
	After				4	14	17	2.29	2.42	928	604
	Test	T	2.43	0.10	2	18	19	2.42	2.47	1030	513
R. S.											
1.95	Fore				3	10	12	1.96	2.02	1048	442
	Test	T	1.07		4	14	17	2.09	2.16	1079	567
	After				5	18	22	2.20	2.28	1006	592
	Test	T	1.21	0.20	4	23	26	2.36	2.50	1021	567
FULL-TERM											
W. B.											
3.37	Fore				2	20	21	3.54	3.52	915	474
	Test	T	3.62		4	21	24	3.52	3.68	1087	588
	After				4	25	28	3.66	3.76	1021	616
	Test	T	3.93	0.20	3	29	31	3.88	4.00	1094	615
	Test			0.20	2	32	33	4.02	4.06	1010	620

* T represents l-tyrosine; PA, d,l-phenylalanine.
† Protein intake = N × 6.25.
‡ Diets consisted of a powdered skimmed milk dilution (alacta) except in R. K. (evaporated cow's milk) and R. F. (powdered whole cow's milk).

TABLE I—*Continued*

Subjects Birth wt.	Experimental period	Supplement fed			Number of days	Age		Weight		Nitrogen average†	
		Amino acid		Ascorbic acid		Start	End	Start	End	Intake‡	Urine
		Type*	Average								
kgm.			*grams per day*			*days*		*kgm.*		*mgm. per kgm. per day*	
PREMATURES											
R. K. 2.08	Fore			0.025	1	22		2.34		720	386
	Test	PA	2.38	0.025	3	23	25	2.36	2.40	777	377
	After			0.025	3	26	28	2.44	2.48	683	413
R. H. E. 2.10	Fore				1	15		2.22		1017	497
	Test	PA	2.30		1	21		2.44		1082	704
	After				1	22		2.43		1006	715
	Test	PA	2.52		4	24	27	2.49	2.59	1085	836
	After				5	28	32	2.63	2.80	936	632
	Test	PA	5.60		1	33		2.81		1140	764
	After	§			1	35		2.93		963	610
A. V. 1.86	Fore				1	25		2.16		988	526
	Test	PA	2.22		2	26	27	2.20	2.20	1055	557
	After				3	28	30	2.20	2.28	996	517
	Test	PA	2.39		5	31	35	2.32	2.44	1038	622
	After				4	36	39	2.50	2.64	983	536
	Test	PA	2.74	0.10	4	40	43	2.70	2.82	1040	545
	After			0.10	6	44	49	2.92	3.08	1000	532
	Test	PA	3.24	0.20	4	50	53	3.20	3.27	1045	576
	After			0.10	2	54	55	3.27	3.28	1020	620
	Test	PA	3.34	0.40	4	56	59	3.30	3.42	1074	696
	After			0.20	2	60	61	3.52	3.54	1013	642
R. Fo. 1.66	Fore				5	17	21	1.87	1.94	1007	488
	Test	PA	0.50		4	22	25	1.98	2.08	1003	494
	After				3	26	28	2.12	2.22	987	523
	Test	PA	0.58	0.20	4	29	32	2.24	2.39	1012	509
	After			0.10	1	33		2.48		960	468
	After				1	36		2.70		935	406
	Test	PA	0.70	0.20	4	37	40	2.76	2.86	1022	497
	After			0.135	5	41	45	2.92	3.08	996	529
	Test	PA	0.79	0.20	4	46	49	3.12	3.24	1011	586
L. G. 2.36	Fore				2	11	12	2.64	2.72	979	435
	Test	PA	1.41		4	13	16	2.78	2.90	1048	433
	After				6	17	22	2.92	3.14	994	520
	Test	PA	1.62	0.20||	4	23	26	3.14	3.36	986	491
	After				2	27	28	3.32	3.40	911	581
FULL-TERM											
R. Fr. 3.50	Fore				1	17		3.88		700	423
	Test	PA	4.06		3	18	20	3.89	4.04	841	373
			9.00		1	21		4.04		930	532
			4.04		1	22		4.04		856	249
	After				6	23	28	4.00	4.16	671	454

§ Received 2 cc. liver extract intramuscularly on 34th and 35th days. || One day only.

High levels of excretion of the ether-soluble aromatic compounds, p-hydroxyphenylpyruvic acid (the keto derivative of tyrosine) and p-hydroxyphenyllactic acid (the hydroxy derivative) were found in 5 premature infants, R. S., J. C., R. Fo., A. V., and R. H. E., and negligible amounts in the 2 full-term infants, W. B. and R. Fr. These results confirm previously reported observations (1, 2). In the 3 premature infants who were not excreting intermediary metabolites in fore-periods, the absence of these could be explained in one by the brief duration of high protein feeding (G. H.); in another, by the prior administration of vitamin C (R. K.). For the third (L. G.), no explanation is at hand.

Recovery of ingested amino acid

Figure 1 shows in graphic form the typical response of 4 subjects to amino acid ingestion, the

increased excretion of urinary constituents above control levels being expressed as percentage of ingested amino acid recovered during test periods of from 3 to 5 days. In the case of R. S., in whom fecal loss of tyrosine was determined, the recovery is calculated as percentage of tyrosine actually absorbed. If data had been available for similar calculations in W. B., the percentage recovery would undoubtedly have been higher than that shown in Figure 1.

Columns 1 and 3 illustrate the recovery of derivatives of ingested tyrosine, and columns 5, 7, and 8, of derivatives of ingested phenylalanine, in the absence of ascorbic acid ingestion. Columns 2, 4, 6, 9, 10, and 11 represent the recovery of in-

gested amino acid with concurrent administration of ascorbic acid. The values for columns 4 and 6 were calculated as percentage increases above original control levels because in each, the second series of amino acid observations with concurrent ingestion of vitamin C was instituted before the rate of excretion of derivatives had returned to their respective basal levels (Table II). The total recovery for the 4 infants shown in Figure 1 plus 4 others, not shown, in whom collections were sufficiently complete to make such calculations, ranged from 40 to 79 per cent when tyrosine was the amino acid ingested and from 43 to 74 per cent when phenylalanine was given.

The pattern of excretion of the various com-

TABLE II

Effect of ingestion of amino acids on urinary excretion of metabolites

Tyrosine															
Subject	Age	Amino acid	Urinary output of derivatives of					Subject	Age	Amino acid	Urinary output of derivatives of				
			Phenylalanine*		Tyrosine†						Phenylalanine*		Tyrosine†		
					Ether-soluble acids		Insoluble tyrosine						Ether-soluble acids		Insoluble tyrosine
			P.P.A.	P.A.	Keto	Oxy					P.P.A.	P.A.	Keto	Oxy	
	days	*grams per kgm.*	*mgm. per 24 hours*						*days*	*grams per kgm.*	*mgm. per 24 hours*				
R. S.	12		7	21	152	284	26	G. H.	9		0	24	3	20	13
	14	0.5	9	19	245	427	37		10	1.0	1	21	50	80	37
	15	0.5	8	22	319	659	74		11	1.0	8	63	259	433	220
	16	0.5	8	27	283	742	107		12	1.0	7	57	251	663	300
	17	0.5	7	28	267	748	109		13	1.0	9	72	251	856	336
	18		7	27	239	727	85		14		5	77	193	419	407‖
	22		8	21	202	279	25		17		0	32	4	16	15
	‡‡23	0.5	1	21	148§		19	J. C.	15		13	63	267	483	94
	‡‡24	0.5	1	15	36		16		16	1.0					
	‡‡25	0.5	1	17	16		13		17	1.0					
	‡‡26	0.5	0	14	16		9		18	1.0					
	27		1	16	20		10		19	1.0	19	69	447	833	167
									20	2.0	21	65	452	886	168
W. B.‡	20		3	25	5	3	10		21		20	49	370	791	92
	21	1.0	4	37	101	10	40		22		20	38	285	596	57
	22	1.0	16	27	394	40	113		23		19	37	274	490	50
	23	1.0	22	38	596	733	264								
	24	1.0	20	38	598	1061	310								
	25		17	32	497	848	197								
	28		15	28	413	510	95								
	‡‡29	1.0	18	28	1198§		180								
	‡‡30	1.0	23	30	1651		240								
	‡‡31	1.0	24	34	1599		216								
	‡‡32		6	30	363		44								
	‡‡33		2	23	22		17								

<div align="center">TABLE II—Continued</div>

<div align="center">Phenylalanine</div>

Left block:

Subject	Age (days)	Amino acid (grams per kgm.)	Phenylalanine* P.P.A.	P.A.	Tyrosine† Ether-soluble acids Keto	Oxy	Insoluble tyrosine
					mgm. per 24 hours		
R. Fo.	21		9	36	235	477	47
	22	0.25	11	127	253	510	45
	23	0.25	12	109	265	499	60
	24	0.25	11	106	277	522	47
	25	0.25	11	125	274	569	64
	26		10	44	286	556	69
	28		8	35	288	503	59
	‡‡29	0.25	9	117		768§	73
	‡‡30	0.25	10	132		648	59
	‡‡31	0.25	7	120		512	44
	‡‡32	0.25	6	136		323	31
	††33		0	24		108	18
	††36		0	33		52	13
	‡‡37	0.25	8	160		310	32
	‡‡38	0.25	16	176		794	63
	‡‡39	0.25	16	181		916	70
	‡‡40	0.25	18	251		1094	86
	††41		11	50		810	64
	††42						
	††43						
	††44						
	‡‡45		0	39		61	20
	‡‡46	0.25	3	203		84	19
	‡‡47	0.25	3	159		104	18
	‡‡48	0.25	5	207		130	22
	‡‡49	0.25	10	204		291	34

Right block:

Subject	Age (days)	Amino acid (grams per kgm.)	Phenylalanine* P.P.A.	P.A.	Tyrosine† Ether-soluble acids Keto	Oxy	Insoluble tyrosine
					mgm. per 24 hours		
A. V.	25		10	41	246	410	50
	26	1.0	36	336	343	561	81
	27	1.0	28	294	405	774	166‖
	28		13	123	384	865	159
	30		9	43	304	494	83
	31	1.0	28	314	419	567	109
	32	1.0	39	499	450	745	262
	33	1.0	51	602	497	851	394‖
	34	1.0	83	724	478	704	489‖
	35	1.0	70	557	506	808	390‖
	36		26	187	582	860	220
	39		11	44	365	531	83
	††40	1.0	36	382	427	549	189
	††41	1.0	52	409	522	661	326
	††42	1.0	71	452	654	856	429‖
	††43	1.0	75	470	689	972	472‖
	††44						
	††45		3	51		240§	48
	††49		0	25		24	16
	‡‡50	1.0	53	503		339	64
	‡‡51	1.0	53	461		1059	224
	‡‡52	1.0	78	656		1469	379
	‡‡53	1.0	86	715		1956	643‖
	††54						
	††55		0	37		102	26
	§§56	1.0	40	708		295	61

ponents and the effect or absence of effect of ascorbic acid, illustrated in Figure 1, will be discussed below.

Effect of tyrosine ingestion

The data (Table II) confirm the previous findings (1, 2) of a prompt, marked, and persistent increase in urinary hydroxyphenyl compounds (p-hydroxyphenylpyruvic acid, 1-p-hydroxyphenyllactic acid, and tyrosine) in the absence of dietary vitamin C. This response occurred with daily dosages of 0.5 to 2.0 grams per kgm., for 4 to 5 days. For example, in R. S. (Table II and Figure 1) who received 0.5 gram of tyrosine per kgm. per day, 78 per cent of the extra tyrosine

absorbed from the gastrointestinal tract was recovered in the urine as tyrosine itself plus its keto and hydroxy derivatives.

The high rate of excretion of the ether-insoluble aromatic fraction, tyrosine, was striking in all 4 infants. It attained such a high level in G. H. (Table II) that his urine, as voided, contained gross crystals of tyrosine.[2]

Cessation of treatment was accompanied by a variable but steady decline in output of these metabolites. In 2 of the premature infants who

[2] These crystals were purified and identified as l-tyrosine by elementary analysis and optical rotation in Dr. V. duVigneaud's laboratory, by his colleagues Dr. G. B. Brown and Dr. J. R. Rachele, to whom we are indebted.

TABLE II—*Continued*

Phenylalanine

Subject	Age	Amino acid	Phenylalanine* P.P.A.	Phenylalanine* P.A.	Tyrosine† Keto	Tyrosine† Oxy	Insoluble tyrosine	Subject	Age	Amino acid	Phenylalanine* P.P.A.	Phenylalanine* P.A.	Tyrosine† Keto	Tyrosine† Oxy	Insoluble tyrosine
	days	*grams per kgm.*	*mgm. per 24 hours*						*days*	*grams per kgm.*	*mgm. per 24 hours*				
L. G.	12		1	21	4	2	11	A. V.	§§57	1.0	80	594	655		114
	13	0.5	5	283	25	20	15		§§58	1.0	56	505	976		136
	14	0.5	14	282	131	98	26		§§59	1.0	92	642	1602		291‖
	15	0.5	35	223	303	259	41		§§60						
	16	0.5	27	234	465	502	87		‡‡61		0	44	27		18
	17		14	38	419	550	65	R. Fr.‡	17		2	31	2	7	14
	22		8	19	316	336	38		18	1.0	102	222	203	128	65
	‡‡23	0.5	5	150	109	160	22		19	1.0	238	774	800	760	643
	24	0.5	15	301	125	168	29		20	1.0					
	25	0.5	23	340	274	461	66		21	2.0	696	2410	720	1321	1347‖
	26	0.5	31	332	530	520	89		22	1.0	145	538	279	649	559‖
	27		16	43	494	615	64		23		38	667	490	1689	975‖
	28		8	30	274	292	59		26		0	36	8	17	37
									28		0	36	5	17	20
R. K.	**22		0	25	4	7	9	R. H. E.	15		9		211	559	72
	**23	1.0	15	263	36	130	25		21		70	322	385	734	139
	**24	1.0	12	298	111	439	140		22		19	119	358	948	136
	**25	1.0	15	393	146	610	372‖		24	1.0					
	**26		0	104	147	637	294		25	1.0	132	973	388	1095	319‖
	**27		0	56	109	433	172		26	1.0					
	**28		0	29	7	40	18		27	1.0	145	974	462	1085	481‖
									28		40	158	434	1113	310‖
									32		21	52	300	579	67
									33¶	2.0	436	3299	459	841	604‖
									¶		116	600	375	787	290
									35		23	114	380	693	198
									‡‡36				63	226	

* P.P.A. represents phenylpyruvic acid; P.A., phenylalanine.

† Keto-acid represents p-hydroxyphenylpyruvic acid; oxy-acid, 1,p-hydroxyphenyllactic acid; both are expressed as tyrosine.

‡ Full-term infant.

§ Combined ether-soluble compounds giving Millon reaction. Keto- and oxy-acids cannot be separated because of interfering action of excreted 1-ascorbic acid.

‖ Crystals of 1-tyrosine in urine.

¶ Twelve-hour periods.

** 0.025 gram of 1-ascorbic acid by mouth daily; he had received 0.8 gram during preceding 11 days.

†† 0.10 gram of 1-ascorbic acid by mouth daily.

‡‡ 0.20 gram of 1-ascorbic acid by mouth daily.

§§ 0.40 gram of 1-ascorbic acid by mouth daily.

received tyrosine, the excretion of the derivatives had returned to the control level within 3 days (G. H. and J. C.) and in the third, after 5 days (R. S.). In the full-term infant (W. B.), it had not reached the control level, which was very low, on the fourth day when subsequent supplements were given.

Attention is directed to the low and relatively constant levels of phenylalanine and its keto acid, phenylpyruvic acid, throughout the pre-, test, and post-periods of tyrosine ingestion. The slight apparent elevation in output of phenylalanine in one infant (G. H.) during tyrosine ingestion was undoubtedly due to the chemical error resulting from

FIG. 1. RECOVERY IN URINE OF EXTRA AMINO ACID INGESTED

1. R. S. Premature. Tyrosine 0.5 gram per kgm. daily for 4 days.
2. Same, with ascorbic acid 0.2 gram daily.
3. W. B. Full-term. Tyrosine 1.0 gram per kgm. daily for 4 days.
4. Same infant; same dosage daily for 3 days; also received ascorbic acid 0.2 gram daily.
5. L. G. Premature. Phenylalanine 0.5 gram per kgm. daily for 5 days.
6. Same; also received a single dose of 0.2 gram ascorbic acid.
7. A. V. Premature. Phenylalanine 1.0 gram per kgm. daily for 2 days.
8. Same infant; same dosage daily for 5 days.
9. Same infant; same dosage for 4 days; also ascorbic acid 0.1 gram daily.
10. Same, except that ascorbic acid dosage was 0.2 gram daily.
11. Same, except that ascorbic acid dosage was 0.4 gram daily.

interference by tyrosine. As previously noted, this error amounted to about 20 mgm. of apparent phenylalanine per 100 mgm. of tyrosine present. In the determinations (R. S. and W. B.) in which tyrosine was removed prior to analysis for phenylalanine, the latter values remained constant.

Effect of phenylalanine ingestion

The rise in urinary excretion of the ether-soluble phenolic compounds, p-hydroxyphenylpyruvic and 1-p-hydroxyphenyllactic acids (Table II), following the ingestion of d,1-phenylalanine, was as

high as or higher than it was after 1-tyrosine in equivalent dosage. Furthermore, the ether-insoluble component, 1-tyrosine, also reached high or higher levels, the amount excreted exceeding its solubility in urine so that all 4 infants (R. K., A. V., R. Fr., and R. H. E.) who received 1.0 gram of phenylalanine per kgm. of body weight per day, actually excreted crystals of 1-tyrosine, identified by chemical analysis.[8]

As might be expected, the increase in output of ether-soluble phenolic compounds and of tyrosine

[8] See footnote 2.

was much less striking in the infants R. Fo. and L. G. who received smaller doses of phenylalanine (0.25 gram and 0.5 gram per kgm. per day, respectively). However, even in the latter infant, the recovery of the ingested dose (Figure 1, column 5) was high, being 70 per cent, of which 52 per cent was in the form of tyrosine derivatives.

The disappearance of metabolites 4 days after cessation of phenylalanine ingestion occurred spontaneously in the full-term infant R. Fr. In the premature infants R. Fo., L. G., A. V., and R. H. E., they were decreasing but were still above the initial levels when a subsequent dose was given, 3 to 6 days after the last preceding one.

The excretion of phenylalanine itself was markedly increased after ingestion of this amino acid, the extent of the overflow being parallel to the size of the dose. An increased output of phenylpyruvic acid began to appear only with the higher phenylalanine dosage, was not great except when phenylalanine overflow was notably high (R. Fr. on the 21st day and R. H. E. on the 33rd day, when each received 2.0 grams of phenylalanine per kgm.), and subsided promptly on cessation of amino acid administration.

Infant A. V. (Figure 1, columns 7 and 8) illustrates well the large proportion of phenylalanine recovered as such and the large amount converted into tyrosine, with a relatively lower but still conspicuous increase in ether-soluble derivatives. In the first test period, in which only 2 doses of phenylalanine of 1.0 gram per kgm. each were given, of a total recovery of 52 per cent, 14 was in the form of phenylalanine and slightly less than 6 per cent as tyrosine; in the second series, in which 5 such doses were given, 54.5 per cent was recovered, of which 21 per cent appeared as phenylalanine and 11 per cent as tyrosine.

Fecal excretion of tyrosine and phenylalanine

The higher urinary output of intermediary metabolites after phenylalanine than after tyrosine ingestion might be due theoretically to its greater metabolizability or to its better absorption from the gastrointestinal tract. That the latter plays a rôle was suspected when curdy stools from infant G. H. were found to contain significant amounts of tyrosine. Consequently, quantitative fecal analyses were carried out in 2 subjects, one receiving phenylalanine and the other tyrosine in equivalent dosage (Table III).

The ingestion by infant L. G. of 0.5 gram of phenylalanine per kgm. per day for 4 days without concurrent vitamin C administration was not accompanied by any significant change in fecal

TABLE III

Fecal excretion of tyrosine and phenylalanine after ingestion of these amino acids

R. S. Age	Intake		Fecest			L. G. Age	Intake		Fecest	
	Tyrosine	Ascorbic acid	Tyrosine	Phenyl-alanine	Ingested tyrosine lost in feces		Phenyl-alanine	Ascorbic acid	Tyrosine	Phenyl-alanine
days	grams		mgm. per 24 hours		per cent	days	grams		mgm. per 24 hours	
10			12	15		11			17	23
11			12	15		12			17	23
12			12	15		13	1.39*		21	16
13						14	1.40		21	16
14	1.045*		192	17		15	1.40		38	26
15	1.050		203	17		16	1.45		38	26
16	1.080		214	24		17			38	26
17	1.100		208	24						
18			29	12	18	21			27	37
21			25	8		22			27	37
22			25	8		23	1.57*	0.2	20	34
23	1.18*	0.2	126	9		24	1.61		20	34
24	1.20	0.2	364	35		25	1.62		19	29
25	1.21	0.2	477	21		26	1.68		19	29
26	1.25	0.2	345	21		27			42	66
27		0.025	63	52	22	28			42	66

* 0.5 gram per kgm. body weight per day.
† Analyses made during fore and after periods on pooled samples of from 1 to 3 days, and daily during the test periods.

output of either amino acid. In contrast, similar dosage of tyrosine in another infant (R. S.) resulted in a notable increase in fecal loss of this amino acid. Cessation of tyrosine ingestion was accompanied by a prompt return to the control levels of fecal loss. However, even when there was the greatest loss (R. S., 24th, 25th, and 26th days), at least two-thirds of the ingested amino acid was absorbed.

Absence of homogentisic acid in urine

At no time was homogentisic acid detected in the urine of either full-term or premature infants, either by darkening of the urine on standing or in a number of specimens on alkalinization and aeration.

Effect of vitamin C

Prevention of excretion of intermediary metabolites in a 4-day period of concurrent daily administration of ascorbic acid and amino acid was accomplished in one premature infant, R. S. (Table II; Figure 1, column 2), whose daily dosages of supplements were tyrosine, 1.21 grams (0.5 gram per kgm.) and ascorbic acid, 0.2 gram. In this infant, the first dose of ascorbic acid preceded the amino acid ingestion by 5 hours.

In one full-term infant given tyrosine (W. B.) and 2 premature infants given phenylalanine (R. Fo. and A. V.), ascorbic acid, administered in liberal amounts 2 to 8 hours before the start of the series of test observations with amino acid and continued daily throughout the period, failed to prevent or to diminish appreciably the output of derivatives in the urine. In one infant (L. G.), a single dose of 1-ascorbic acid (0.2 gram), given on the first day of a series of test observations with phenylalanine (0.5 gram per kgm. per day for 4 days), was without significant effect on the excretion of aromatic derivatives (Table II).

In R. K., ascorbic acid was given for a number of days prior to amino acid ingestion with the purpose of saturating the infant's tissues. Although the absence of aromatic compounds in the urine during the control period presumably reflects the accomplishment of this object, the vitamin did not prevent the excretion of large amounts of all the derivatives, including tyrosine crystals, when phenylalanine was administered (Table II).

Contrary to expectation, no relationship ap-

peared to exist between the dosage of ascorbic acid and its effect. The pattern of excretion is closely similar in R. K., receiving 25 mgm. of the vitamin daily, to that in A. V., receiving increasing amounts up to 400 mgm. daily. In Figure 1, columns 9, 10, and 11 show strikingly the complete lack of effect of even these high dosages on the urinary recovery of ingested phenylalanine and its derivatives. The 200 mgm. of vitamin given daily to R. Fo. in the series from the 29th to the 32nd day was divided into 2 equal doses, whereas from the 37th to the 40th and from the 45th to the 49th days the same total daily amount was subdivided into 6 doses. Although saturation with respect to vitamin C might be expected to be better maintained with the frequent dosage, it did not prevent the defect in metabolism of ingested phenylalanine.

Fecal excretion of ingested tyrosine and phenylaline (Table III) was not significantly affected by concurrent administration of vitamin C.

The one consistently positive effect of ascorbic acid as shown in the preceding papers (1, 2) was the rapid disappearance of derivatives after amino acid ingestion was stopped. This result was obtained in all of the infants who received supplements of vitamin C in the post-periods. This effect is strikingly illustrated in infant W. B. (Table II) by contrasting the figures for the 33rd day with ascorbic acid ingestion and those of the 25th and 28th days without vitamin supplements; in R. Fo., on the 33rd and 36th days in contrast to the 26th and 28th; and in A. V., on the 45th and 49th days in contrast to the 36th and 39th. This prompt drop in the case of A. V. recurred at the end of 2 other test periods of combined amino acid and vitamin ingestion (55th and 61st days). In R. K. also, there was a disappearance of the derivatives within 3 days after the cessation of ingestion of amino acid.

DISCUSSION

These observations suggest that in healthy human beings (premature and full-term infants) as in the animal studies cited (3 to 9), 1-tyrosine can be formed from d,1-phenylalanine. This conversion proceeded to such a degree that one or 2 days after the first of a series of daily oral doses of phenylalanine of 1.0 gram per kgm. of body weight, the urinary excretion of tyrosine in these

subjects exceeded its solubility and gross crystals of this substance were voided in the urine.

The reverse conversion did not occur. When tyrosine was ingested, this compound itself, as well as its keto and oxy derivatives, was excreted in large amounts, but the urinary output of phenylalanine and its keto acid, phenylpyruvic, remained minimal. This finding is consistent with the observations of Womack and Rose (5) that tyrosine in the diet of rats cannot replace the essential phenylalanine.

Assay of the feces revealed that absorption of ingested phenylalanine was practically complete. Tyrosine, on the other hand, was not completely absorbed, 18 to 22 per cent of ingested tyrosine being recovered in the feces of one subject.

Premature infants receiving a diet containing 5 to 7 grams of protein per kgm. (providing a total of about 0.5 gram of tyrosine plus phenylalanine per kgm.), as in previous studies (1, 2), excreted in the urine large amounts of p-hydroxyphenylpyruvic acid and p-hydroxyphenyllactic acid. Even with high initial levels, further repeated administration of tyrosine or phenylalanine in pure form led to the recovery of 40 to 70 per cent of the ingested amino acid and its derivatives. Similar recoveries were obtained in 2 full-term infants who were receiving the same high protein diet but whose control levels of aromatic compounds in the urine were extremely low.

The effect of ascorbic acid, previously shown (1, 2.b) to prevent the rise of metabolites when a single dose of either amino acid was given, was not manifest in these observations with repeated dosage except in one infant in whom 200 mgm. of ascorbic acid daily prevented the appearance of derivatives of 0.5 gram of tyrosine per kgm. per day (W. B.). The principal difference in the present study from the earlier ones was the repeated and relatively high dosage of amino acids. Presumably this high dosage overwhelmed the vitamin's opposing action, the nature of which is still in the realm of study rather than of established fact (20). Even with such large dosage, it is noteworthy than when amino acid administration was stopped, ascorbic acid was then able to exert its usual effect, shown by the rapid drop in excretion of the derivatives in contrast to their persistence when no ascorbic acid was given.

The absence of homogentisic acid in the urine

of these subjects, in contrast to the results of Sealock and his colleagues (7, 20) with guinea pigs, appears to be due to a specific difference rather than, as suggested by Sealock (20) in referring to the earlier papers (1, 2), to small dosage of the amino acids.

As in the previous work (2.a), it was again found that more p-hydroxyphenyllactic acid was excreted than p-hydroxyphenylpyruvic acid, in contrast to the results reported in animals (7.b) in which the 2 ether-soluble tyrosine derivatives were present in reverse proportions.

Another point worthy of brief mention is the extremely small amount of phenylpyruvic acid excreted, except in 2 instances when 2.0 grams per kgm. of phenylalanine was administered. Even then the highest amounts excreted were less than 0.7 gram per day, in contrast to several grams usually eliminated by subjects with phenylpyruvic oligophrenia (14).

SUMMARY

Ten healthy male infants, 8 premature and 2 full-term, were observed while on constant high-protein, vitamin C-free diets. These diets were calculated to contain about 0.5 gram of tyrosine plus phenylalanine per kgm. of body weight. Various dosages of extra l-tyrosine and d,l-phenylalanine were administered in pure form and the urine quantitatively collected and analyzed for these aromatic amino acids and their derivatives. In some of the test periods, ascorbic acid was also given.

In both premature and full-term infants, the repeated ingestion of d,l-phenylalanine resulted in the appearance in the urine not only of this amino acid but also of l-tyrosine and its derivatives, p-hydroxyphenylpyruvic acid and p-hydroxyphenyllactic acid, in large amounts. When the daily dosage of phenylalanine was 1.0 gram per kgm., the excretion of tyrosine exceeded its solubility in the urine so that gross crystals of this amino acid were voided. The sum of the aromatic amino acids and their derivatives recovered in the urine, above the amounts present in control periods, represented 44 to 73 per cent of the extra phenylalanine ingested.

This reaction is apparently irreversible, as shown by the absence of significant excretion of phenylalanine and phenylpyruvic acid after equivalent l-tyrosine ingestion, though tyrosine and its keto

and hydroxy derivatives appeared in abundant amounts, accounting for 40 to 80 per cent of the ingested or absorbed amino acid.

These results suggest that in the human organism, as in lower animals, 1-tyrosine in the diet cannot replace, d,l-phenylalanine which, in animals, has been shown to be essential.

Analyses of the feces of 2 subjects showed that no appreciable amount of phenylalanine is lost by this route, whereas 18 to 22 per cent of ingested tyrosine may be excreted in the feces.

Even with large repeated dosage of the amino acids, the babies, unlike guinea pigs and rats, did not excrete homogentisic acid.

Vitamin C (1-ascorbic acid), previously shown to diminish or abolish the excretion of aromatic metabolites after single dosage of either amino acid, was, except in one infant, ineffective when jointly given with repeated and large dosage of either tyrosine or phenylalanine. The usual vitamin effect reappeared promptly on cessation of amino acid ingestion, as evidenced by rapid disappearance of the derivatives from the urine.

BIBLIOGRAPHY

1. Levine, S. Z., Marples, E., and Gordon, H. H., A defect in the metabolism of aromatic amino acids in premature infants: The role of vitamin C. Science, 1939, 90, 620.
2. a. Levine, S. Z., Marples, E., and Gordon, H. H., A defect in the metabolism of tyrosine and phenylalanine in premature infants. I. Identification and assay of intermediary products. J. Clin. Invest., 1941, 20, 199.
   b. Levine, S. Z., Gordon, H. H., and Marples, E., A defect in the metabolism of tyrosine and phenylalanine in premature infants. II. Spontaneous occurrence and eradication by vitamin C. J. Clin. Invest., 1941, 20, 209.
3. Embden, G., and Baldes, K., Ueber den Abbau des Phenylalanins im tierischen Organismus. Biochem. Ztschr., 1913, 55, 301.
4. Embden, G., and Schmitz, G., Ueber synthetische Bildung von Aminosäuren in der Leber. Biochem. Ztschr., 1910, 29, 423.
5. Womack, M., and Rose, W. C., Feeding experiments with mixtures of highly purified amino acids. VI. The relation of phenylalanine and tyrosine to growth. J. Biol. Chem., 1934, 107, 449.
6. Papageorge, E., and Lewis, H. B., Comparative studies of the metabolism of the amino acids. VII. Experimental alcaptonuria in the white rat. J. Biol. Chem., 1938, 123, 211.
7. a. Sealock, R. R., and Silberstein, H. E., Control of experimental alcaptonuria by means of vitamin C. Science, 1939, 90, 517.
   b. Sealock, R. R., and Silberstein, H. E., The excretion of homogentisic acid and other tyrosine metabolites by the vitamin C-deficient guinea pig. J. Biol. Chem., 1940, 135, 251.
8. Kotake, Y., Masai, Y., and Mori, Y., Ueber das Verhalten des Phenylalanins im tierischen Organismus. Ztschr. f. physiol. Chem., 1922, 122, 195.
9. Moss, A. R., and Schoenheimer, R., The conversion of phenylalanine to tyrosine in normal rats. J. Biol. Chem., 1940, 135, 415.
10. Moss, A. R., The conversion of β-phenyllactic acid to tyrosine in normal rats. J. Biol. Chem., 1941, 137, 739.
11. a. Neubauer, O., and Falta, W., Ueber das Schicksal einiger aromatischer Säuren bei der Alkaptonurie. Ztschr. f. physiol. Chem., 1904, 42, 81.
    b. Neubauer, O., Ueber den Abbau der Aminosäuren im gesunden und kranken Organismus. Deutsches Arch. f. klin. Med., 1909, 95, 211.
12. Sealock, R. R., Galdston, M., and Steele, J. M., Administration of ascorbic acid to an alkaptonuric patient. Proc. Soc. Exper. Biol. and Med., 1940, 44, 580.
13. Medes, G., A new error of tyrosine metabolism: tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine. Biochem, J., 1932, 26, 917.
14. a. Jervis, G. A., Metabolic investigations on a case of phenylpyruvic oligophrenia. J. Biol. Chem., 1938, 126, 305.
    b. Dann, M., Marples, E., and Levine, S. Z., Phenylpyruvic oligophrenia. Report of a case in an infant with quantitative chemical studies of the urine. J. Clin. Invest., 1943, 22, 87.
15. Bessey, O. A., A method for the determination of small quantities of ascorbic acid and dehydroascorbic acid in turbid and colored solutions in the presence of other reducing substances. J. Biol. Chem., 1938, 126, 771.
16. a. Hoag, L. A., Apparatus for quantitative collection of urine and of stools in male infants. Am. J. Dis. Child., 1932, 44, 770.
    b. Gordon, H. H., Levine, S. Z., Wheatley, M. A., and Marples, E., Respiratory metabolism in infancy and in childhood. XX. The nitrogen metabolism in premature infants: Comparative studies of human milk and cow's milk. Am. J. Dis. Child., 1937, 54, 1030.
17. Folin, O., and Ciocalteu, V., On tyrosine and tryptophane determinations in proteins. J. Biol. Chem., 1927, 73, 627.
18. Kapeller-Adler, R., Ueber eine neue Reaktion zur qualitativen und quantitativen Bestimmung des Phenylalanins. Biochem. Ztschr., 1932, 252, 185.
19. Jervis, G. A., Block, R. J., Bolling, D., and Kanze, E., Chemical and metabolic studies on phenylalanine. II. The phenylalanine content of the blood and spinal fluid in phenylpyruvic oligophrenia. J. Biol. Chem., 1940, 134, 105.
20. Sealock, R. R., The relation of vitamin C to the metabolism of the aromatic amino acids. Federation Proceedings, 1942, 1, 287.